Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis

Meei Maan Wu, Hung Yi Chiou, Yu Mei Hsueh, Chi Tzong Hong, Che Long Su, Shu Feng Chang, Wen Ling Huang, Hui Ting Wang, Yuan Hung Wang, Yi Chen Hsieh, Chien Jen Chen

研究成果: 雜誌貢獻文章

54 引文 (Scopus)

摘要

Arsenic-contaminated well water has been shown to increase the risk of atherosclerosis. Because of involving S-adenosylmethionine, homocysteine may modify the risk by interfering with the biomethylation of ingested arsenic. In this study, we assessed the effect of plasma homocysteine level and urinary monomethylarsonic acid (MMAV) on the risk of atherosclerosis associated with arsenic. In total, 163 patients with carotid atherosclerosis and 163 controls were studied. Lifetime cumulative arsenic exposure from well water for study subjects was measured as index of arsenic exposure. Homocysteine level was determined by high-performance liquid chromatography (HPLC). Proportion of MMAV (MMA%) was calculated by dividing with total arsenic species in urine, including arsenite, arsenate, MMAV, and dimethylarsinic acid (DMAV). Results of multiple linear regression analysis show a positive correlation of plasma homocysteine levels to the cumulative arsenic exposure after controlling for atherosclerosis status and nutritional factors (P < 0.05). This correlation, however, did not change substantially the effect of arsenic exposure on the risk of atherosclerosis as analyzed in a subsequent logistic regression model. Logistic regression analyses also show that elevated plasma homocysteine levels did not confer an independent risk for developing atherosclerosis in the study population. However, the risk of having atherosclerosis was increased to 5.4-fold (95% CI, 2.0-15.0) for the study subjects with high MMA% (≥16.5%) and high homocysteine levels (≥12.7 μmol/l) as compared to those with low MMA% (<9.9%) and low homocysteine levels (<12.7 μmol/l). Elevated homocysteinemia may exacerbate the formation of atherosclerosis related to arsenic exposure in individuals with high levels of MMA% in urine. © 2006 Elsevier Inc. All rights reserved.
原文英語
頁(從 - 到)168-175
頁數8
期刊Toxicology and Applied Pharmacology
216
發行號1
DOIs
出版狀態已發佈 - 十月 1 2006

指紋

Carotid Artery Diseases
Arsenic
Homocysteine
Plasmas
Atherosclerosis
Logistic Models
Logistics
Regression Analysis
Urine
Cacodylic Acid
monomethylarsonic acid
S-Adenosylmethionine
Water
High performance liquid chromatography
Nutritional Status
Linear regression
Regression analysis
Linear Models
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

引用此文

Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis. / Wu, Meei Maan; Chiou, Hung Yi; Hsueh, Yu Mei; Hong, Chi Tzong; Su, Che Long; Chang, Shu Feng; Huang, Wen Ling; Wang, Hui Ting; Wang, Yuan Hung; Hsieh, Yi Chen; Chen, Chien Jen.

於: Toxicology and Applied Pharmacology, 卷 216, 編號 1, 01.10.2006, p. 168-175.

研究成果: 雜誌貢獻文章

@article{263ab41d950d4398a1c5a03a3ebcabc3,
title = "Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis",
abstract = "Arsenic-contaminated well water has been shown to increase the risk of atherosclerosis. Because of involving S-adenosylmethionine, homocysteine may modify the risk by interfering with the biomethylation of ingested arsenic. In this study, we assessed the effect of plasma homocysteine level and urinary monomethylarsonic acid (MMAV) on the risk of atherosclerosis associated with arsenic. In total, 163 patients with carotid atherosclerosis and 163 controls were studied. Lifetime cumulative arsenic exposure from well water for study subjects was measured as index of arsenic exposure. Homocysteine level was determined by high-performance liquid chromatography (HPLC). Proportion of MMAV (MMA{\%}) was calculated by dividing with total arsenic species in urine, including arsenite, arsenate, MMAV, and dimethylarsinic acid (DMAV). Results of multiple linear regression analysis show a positive correlation of plasma homocysteine levels to the cumulative arsenic exposure after controlling for atherosclerosis status and nutritional factors (P < 0.05). This correlation, however, did not change substantially the effect of arsenic exposure on the risk of atherosclerosis as analyzed in a subsequent logistic regression model. Logistic regression analyses also show that elevated plasma homocysteine levels did not confer an independent risk for developing atherosclerosis in the study population. However, the risk of having atherosclerosis was increased to 5.4-fold (95{\%} CI, 2.0-15.0) for the study subjects with high MMA{\%} (≥16.5{\%}) and high homocysteine levels (≥12.7 μmol/l) as compared to those with low MMA{\%} (<9.9{\%}) and low homocysteine levels (<12.7 μmol/l). Elevated homocysteinemia may exacerbate the formation of atherosclerosis related to arsenic exposure in individuals with high levels of MMA{\%} in urine. {\circledC} 2006 Elsevier Inc. All rights reserved.",
keywords = "Arsenic, Atherosclerosis, Biomethylation, Homocysteine, Risk factors",
author = "Wu, {Meei Maan} and Chiou, {Hung Yi} and Hsueh, {Yu Mei} and Hong, {Chi Tzong} and Su, {Che Long} and Chang, {Shu Feng} and Huang, {Wen Ling} and Wang, {Hui Ting} and Wang, {Yuan Hung} and Hsieh, {Yi Chen} and Chen, {Chien Jen}",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/j.taap.2006.05.005",
language = "English",
volume = "216",
pages = "168--175",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis

AU - Wu, Meei Maan

AU - Chiou, Hung Yi

AU - Hsueh, Yu Mei

AU - Hong, Chi Tzong

AU - Su, Che Long

AU - Chang, Shu Feng

AU - Huang, Wen Ling

AU - Wang, Hui Ting

AU - Wang, Yuan Hung

AU - Hsieh, Yi Chen

AU - Chen, Chien Jen

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Arsenic-contaminated well water has been shown to increase the risk of atherosclerosis. Because of involving S-adenosylmethionine, homocysteine may modify the risk by interfering with the biomethylation of ingested arsenic. In this study, we assessed the effect of plasma homocysteine level and urinary monomethylarsonic acid (MMAV) on the risk of atherosclerosis associated with arsenic. In total, 163 patients with carotid atherosclerosis and 163 controls were studied. Lifetime cumulative arsenic exposure from well water for study subjects was measured as index of arsenic exposure. Homocysteine level was determined by high-performance liquid chromatography (HPLC). Proportion of MMAV (MMA%) was calculated by dividing with total arsenic species in urine, including arsenite, arsenate, MMAV, and dimethylarsinic acid (DMAV). Results of multiple linear regression analysis show a positive correlation of plasma homocysteine levels to the cumulative arsenic exposure after controlling for atherosclerosis status and nutritional factors (P < 0.05). This correlation, however, did not change substantially the effect of arsenic exposure on the risk of atherosclerosis as analyzed in a subsequent logistic regression model. Logistic regression analyses also show that elevated plasma homocysteine levels did not confer an independent risk for developing atherosclerosis in the study population. However, the risk of having atherosclerosis was increased to 5.4-fold (95% CI, 2.0-15.0) for the study subjects with high MMA% (≥16.5%) and high homocysteine levels (≥12.7 μmol/l) as compared to those with low MMA% (<9.9%) and low homocysteine levels (<12.7 μmol/l). Elevated homocysteinemia may exacerbate the formation of atherosclerosis related to arsenic exposure in individuals with high levels of MMA% in urine. © 2006 Elsevier Inc. All rights reserved.

AB - Arsenic-contaminated well water has been shown to increase the risk of atherosclerosis. Because of involving S-adenosylmethionine, homocysteine may modify the risk by interfering with the biomethylation of ingested arsenic. In this study, we assessed the effect of plasma homocysteine level and urinary monomethylarsonic acid (MMAV) on the risk of atherosclerosis associated with arsenic. In total, 163 patients with carotid atherosclerosis and 163 controls were studied. Lifetime cumulative arsenic exposure from well water for study subjects was measured as index of arsenic exposure. Homocysteine level was determined by high-performance liquid chromatography (HPLC). Proportion of MMAV (MMA%) was calculated by dividing with total arsenic species in urine, including arsenite, arsenate, MMAV, and dimethylarsinic acid (DMAV). Results of multiple linear regression analysis show a positive correlation of plasma homocysteine levels to the cumulative arsenic exposure after controlling for atherosclerosis status and nutritional factors (P < 0.05). This correlation, however, did not change substantially the effect of arsenic exposure on the risk of atherosclerosis as analyzed in a subsequent logistic regression model. Logistic regression analyses also show that elevated plasma homocysteine levels did not confer an independent risk for developing atherosclerosis in the study population. However, the risk of having atherosclerosis was increased to 5.4-fold (95% CI, 2.0-15.0) for the study subjects with high MMA% (≥16.5%) and high homocysteine levels (≥12.7 μmol/l) as compared to those with low MMA% (<9.9%) and low homocysteine levels (<12.7 μmol/l). Elevated homocysteinemia may exacerbate the formation of atherosclerosis related to arsenic exposure in individuals with high levels of MMA% in urine. © 2006 Elsevier Inc. All rights reserved.

KW - Arsenic

KW - Atherosclerosis

KW - Biomethylation

KW - Homocysteine

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=33748747684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748747684&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2006.05.005

DO - 10.1016/j.taap.2006.05.005

M3 - Article

VL - 216

SP - 168

EP - 175

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 1

ER -